PGI56 The Burden of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In France: A Comparison With The European Results From The Ibis-C Observational Study  by Coffin, B et al.
A632  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
PGI56
The Burden of ModeraTe-To-Severe IrrITaBle Bowel SyndroMe wITh 
ConSTIPaTIon (IBS-C) In franCe: a CoMParISon wITh The euroPean 
reSulTS froM The IBIS-C oBServaTIonal STudy
Coffin B1, Follet M2, Mackinnon J3, Bertsch J3, Fortea J4, Tack J5
1Louis-Mourier Hospital, Colombes, France, 2Almirall SAS, Paris, France, 3TFS Develop S.L, 
Barcelona, Spain, 4Almirall S.A, Barcelona, Spain, 5University Hospital Gasthuisberg, Leuven, 
Belgium
Objectives: To describe the population of moderate-to-severe IBS-C patients in 
French clinical practice and to compare the main data with the European data from 
the IBIS-C study. The IBIS-C study was conducted in six European countries (France, 
Germany, Italy, Spain, Sweden and UK). MethOds: Observational, retrospective-
prospective (6 months each) study of patients diagnosed (Rome-III criteria) in the 
last five years and moderate-to-severe IBS-C severity at inclusion (IBS-Symptom 
Severity Scale [IBS-SSS] score ≥ 175). Healthcare resource utilisation (HRU) was ret-
rospectively and prospectively assessed and quality-of-life (QoL) was assessed at 
baseline with IBS-QoL and EuroQoL-5D (EQ-5D). Results: Patient characteristics 
were similar between the French (n= 59) and European (n= 525) cohorts: mean (±SD) 
age 47.7±15.7 and 45.3±15.8 years; 83% and 87% were female, and 63% and 60% had 
severe IBS-C. Mean symptom duration: 13.5±13.5 and 12.8±13.1 years; mean time 
since diagnosis: 2.6±6.3 and 3.0±5.2 years. At baseline, mean IBS-QoL was 42.9±19.0 
and 54.9±22.7 (scale: 0-100[worst-best]); mean EQ-5D was 46.6±22.2 and 55.5±21.7 
(scale: 0-100[worst-best]). Over follow-up, 76% French and 73% European patients 
consulted a GP (mean: 4.2 and 4.9 visits), and 100% and 92% a gastroenterologist 
(mean: 2.2 and 2.8 visits). 17% and 18% required emergency department visits/hos-
pitalisation (mean stay: 6±6 and 14±24 days). 51% and 65% of patients took prescrip-
tion drugs for their IBS-C, 61% and 67% took non-prescription drugs. Mean symptom 
severity (IBS-SSS) improved: 338.9±78.6 (baseline) to 281.5±102.1 (6 months) for the 
French cohort; 323.2±84.3 to 253.9±105.6 for the European cohort. The total mean 
(95%CI) annual cost for moderate-to-severe IBS-C was € 4,128 (2,262-6,633) for 
the French cohort; € 4,639 (3,733-5,598) for the European cohort. cOnclusiOns: 
Moderate-to-severe IBS-C symptoms in France were similar to those other European 
countries. QoL impairment and HRU were high for both cohorts. Moderate-to-severe 
IBS-C continued to be a burden for both cohorts with a high economic cost despite 
availability of therapeutic interventions.
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Objectives: To understand medical resource utilisation (MRU) of Australian 
patients with genotype 1 chronic hepatitis C (GT1 CHC) including those receiv-
ing current standard of care treatment (telaprevir or boceprevir with pegylated 
interferon and ribavirin). MethOds: Medical records were reviewed for a strati-
fied random sample of GT1 CHC patients first attending two liver clinics between 
2011 and 2013 (principal population; PP) supplemented by all GT1 CHC patients 
attending one transplant clinic in the same period (transplant population; TP). 
CHC-related MRU (percentage and annual rate [poisson] of outpatient, hospitali-
sation, laboratory and imaging tests) is reported for the PP by treatment status 
(treated/not treated) stratified by fibrosis grade; and for TP pre-transplant, year 
of transplant and post-transplant. Results: Comprehensive MRU was collected 
for 276 PP patients (F0-1 n= 59, F2 n= 58, F3 n= 53, F4 n= 106; 38 were treatment 
experienced prior to first visit; mean follow-up 17.6 months). Fifty-five (19.9%) 
received triple therapy. Data were collected for 112 TP patients (mean follow-up 
29.9 months), 33 (29.5%) received a transplant during the study and 51 (45.5%) 
beforehand. MRU was higher while treated including annual rates of outpatient 
visits (PP: 9.67 vs 2.91 [F0-1 2.60, F2 2.56, F3 2.63, F4 3.33]; TP: transplant 18.00 vs 
pre 5.55, post 5.14), psychiatric visits (PP: 0.71 vs 0.18 [F0-1 0.25, F2 0.16, F3 0.20, 
F4 0.14]; TP: transplant 0.00 vs pre 0.50, post 0.01), nurse visits (PP: 1.84 vs 0.42 
[F0-1 0.58, F2 0.42, F3 0.51, F4 0.32]); and the percentage with hospitalisation (PP: 
27.3% vs 13.0% [F0-1 3.4%, F2 10.3%, F3 9.4%, F4 21.7%]; TP: transplant 100% vs pre 
96.5%, post 79.2%). cOnclusiOns: CHC-related MRU increases substantially with 
disease severity. To our knowledge, these are the first real-world MRU reported 
for GT1 CHC in Australia and will be valuable in assessing the impact of new 
hepatitis C treatments.
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Objectives: To evaluate the landscape of health technology assessment (HTA) 
decisions for chronic hepatitis C (CHC) therapies in Canada (CADTH), Australia 
(PBAC), England and Wales (NICE), Scotland (SMC), Germany (IQWiG), and France 
(HAS). MethOds: Selected HTA agency websites were searched for submissions 
made in the CHC therapy area. Submissions were searched for following informa-
tion: clinical and economic input provided in the submission, recommendations 
from HTA agencies, and drivers of HTA decisions. Results: Victrelis®, Daklinza®, 
Roferon A®, Intron A®, Harvoni®, Viekirax®, Pegasys RBV®, PegIntron®, Rebetol®, 
Olysio®, Sovaldi®, and Incivo® were the pharmacotherapies for which manufac-
turer submissions were available across selected agencies. The number of HTA 
submissions with completion status ranged from 6-12. The percentage recommen-
dation ranged from 43% in Australia to 100% in France and Canada. The number 
of clinical studies supporting the manufacturer submission ranged from 2-12. The 
status, and treatment patterns. Physicians were screened for duration of prac-
tice (≥ 3yrs) and patient volume (≥ 15 HCV patients/mo) and recruited from a 
large panel to be geographically representative. Medical charts of the next 10 
consecutive HCV patients were abstracted. G1 HCV patient data was ana-
lyzed. Results: 2067 eligible G1 HCV patients were included in the analysis 
(France:374/Germany:506/Italy:412/Spain:475/UK:300). Patient characteristics 
included (France/Germany/Italy/Spain/UK) - mean age (yrs):53/49/55/52/45; male: 
61%/67%/61%/59%/69%; patient weight < = 80kg:81%/66%/83%/74%/76%; major-
ity were G1-subtype A (52%/44%/31%/34%/68%) or B (48%/54%/68%/66%/32%); 
any substance-abuse:23%/18%/10%/17%/47%; route of infection via intravenous 
drug use:55%/33%/31%/41%/69%, via blood transfusion:19%/26%/21%/36%/7%, 
via heterosexual contact:5%/11%/22%/11%/7%, via homosexual con-
tact:8%/13%/10%/6%/12%; current fibrosis scores were – F0:9%/18%/6%/7%/20%, 
F1:18%/30%/25%/25%/32%, F2:24%/28%/32%/24%/18%, F3:21%/17%/17%/20%/11%, 
F4:29%/6%/20%/23%/19%. In France/Germany/Italy/Spain/UK, latest mean alanine 
aminotransferase levels were:58/90/95/62/73; patients with undetectable (0-500) 
viral load (VL):5%/2%/25%/2%/1%; 501-< = 1Million VL-count:58%/39%/52%/75%; > 1M 
VL-count:38%/26%/38%/45%/25%. Treatment patterns included (France/Germany/
Italy/Spain/UK)- currently treated:23%/28%/20%/17%/20%, not currently treated 
(previous treatment non-responder, discontinued or relapsed, or therapy com-
plete and awaiting sustained viral response):21%/20%/29%/30%/22%, not current 
treated because patient achieved sustained viral response:19%/12%/11%/13%/6%; 
treatment naïve/never been treated:38%/40%/41%/41%/52%. cOnclusiOns: 
In this cohort of G1 HCV patients, treatment rates and disease burden varied 
among studied countries in EU; only a small proportion of patients had unde-
tectable VL or was not treated owing to achieving sustained viral response. 
Further research is warranted to assess the observed treatment patterns, effec-
tiveness of regimens, and patient management strategies to alleviate patient 
burden.
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Objectives: The analysis aimed to evaluate the evolution of the national and 
regional public expenditure regarding Proton Pump Inhibitors (PPIs) in Italy, in 
relation to national and regional policies. MethOds: The analysis combined 
data published by the Italian Medicines Agency (AIFA) and Regions and regional 
and national laws, to understand the impact of the applied policies on PPIs 
expenditure. Results: Over the past ten years, PPIs consumption increased 
by 280% (around 14% yearly), with lansoprazole reaching +533%. The number 
of patients ≥ 18 treatable with PPIs in 2013 was 2.873.500 (6% of adult popu-
lation), being the first class in terms of expenditure with a per capita value of 
15.2€ and consumptions of 74 DDD/1.000 inh./die. Consumptions and expenditure 
incresed by respectively 6.5% and 1.6% vs 2012. AIFA also highlighted a trend to 
prescriptive inappropiateness over the years, where the 46.5% of patients do not 
meet the reimbursability criteria by law. At regional level, Regions have issued 
a number of regional laws to contain both consumptions and expenditure (e.g. 
through reference pricing or guidelines to encourage the prescription of generi-
cated drugs), identifying specific performance indicators and target values. We 
estimated potential savings from the correct application of the reimburability 
criteria amounting to 260 million € /year, if Regions were able to control pre-
scriptive appropriateness, to which additional savings could be added through 
focused cost-containment measures. cOnclusiOns: Despite a number of 
efforts at both central and regional level, the trend towards inappropriateness 
and expenditure increase of PPIs is confirmed. A review of both national and 
regional policies on PPIs expenditure is key to reduce the current waste of eco-
nomic resources and, with a stable total budget, guarantee additional funding for 
innovation.
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Objectives: Comprehensive assessment of the financial costs of drug treatment of 
nonalcoholic steatohepatitis (NASH) in a hospital of Kharkiv, Ukraine. MethOds: 
For the study, the schemes medicinal histories of 54 patients with NASH in a hos-
pital in Kharkov during 2013 were used. The structure of costs of NASH treatment 
was assessed by the ABC analysis. Assessment of the level of NASH treatment cor-
respondence was conducted by the formal VEN analysis according to the National 
Drug Formulary (NDF) of Ukraine (2013). Index “V” was put in case of availability of 
the drug in the NDF, index “N” – in case of its absence. Directions of NASH treat-
ment were assessed by the prescriptions of drugs according to requirements of 
Ukrainian Cinical Guidelines (O.Ia. Babak, 2007) and according to Practice Guideline 
by the American Association for the Study of Liver Diseases (AASLD) for 2012. In 
determining the cost of drugs, their prices as of May 2015 by the data of Morion 
reference and retrieval system “Drugs” were used. Results: Drug treatment of 
patients with NASH by pharmacotherapeutic groups met the basic requirements 
of Ukrainian Clinical Guidelines and Guidelines of American scientists AASLD, 
which confirms the rationality of prescriptions. According to the ABC/VEN analy-
sis, most of the funds for treatment (82%) were spent on 76% of drugs included in 
the NDF. But 24% of drugs were missing from the NDF of Ukraine, indicating the 
need to correct NASH treatment in the hospital of Ukraine. cOnclusiOns: 76% 
of drugs prescribed to patients with NASH can be considered rational, but 24% of 
drugs had index “N”, indicating their inappropriate use. Comparison of the ABC 
and VEN analysis showed the need to correct NASH treatment in the hospital of 
Ukraine, as 18% of funds were spent on minor drugs which are not represented 
the NDF of Ukraine.
